BACKGROUND: Monoclonal B-cells can be detected in the peripheral blood of some adults without B-cell malignancies, a condition recently termed monoclonal B-cell lymphocytosis (MBL). The risk of individuals with MBL progressing to a B-cell malignancy is unknown. Polyclonal B-cell lymphocytosis (PCBL) has not been systematically studied in the general population. METHODS: We obtained lymphocyte subset counts on 1,926 residential adults aged 40-76 years in a series of environmental health studies between 1991 and 1994. We then conducted two follow-ups in 1997 and 2003 on consenting participants with B-cell lymphocytosis, which included nine participants with MBL. To ascertain the clinical implications of MBL, we reviewed medical records and death certificates. RESULTS: The overall prevalence of MBL was 0.57% (11/1,926): nine cases at baseline and two additional cases identified at follow-up. Two (19%) MBL cases subsequently developed a B-cell malignancy; MBL persisted in the remaining nine cases (81%). All PCBL cases where no clone emerged regressed to normal B-cell counts over the follow-up period. MBL was significantly more frequent in residents near a hazardous waste site than in the control populations (age-adjusted OR 6.2; 95%CI 1.1-36.2). CONCLUSION: MBL confers an elevated risk for developing a B-cell malignancy, although it occurs only in a minority of cases. PCBL is most often a transient state, but a monoclonal population can emerge and persist. Prospective studies are needed to distinguish stable from progressive forms of B-cell lymphocytosis and to clarify the etiologic role of environmental exposures. Published 2007 Wiley-Liss, Inc.
BACKGROUND: Monoclonal B-cells can be detected in the peripheral blood of some adults without B-cell malignancies, a condition recently termed monoclonal B-cell lymphocytosis (MBL). The risk of individuals with MBL progressing to a B-cell malignancy is unknown. Polyclonal B-cell lymphocytosis (PCBL) has not been systematically studied in the general population. METHODS: We obtained lymphocyte subset counts on 1,926 residential adults aged 40-76 years in a series of environmental health studies between 1991 and 1994. We then conducted two follow-ups in 1997 and 2003 on consenting participants with B-cell lymphocytosis, which included nine participants with MBL. To ascertain the clinical implications of MBL, we reviewed medical records and death certificates. RESULTS: The overall prevalence of MBL was 0.57% (11/1,926): nine cases at baseline and two additional cases identified at follow-up. Two (19%) MBL cases subsequently developed a B-cell malignancy; MBL persisted in the remaining nine cases (81%). All PCBL cases where no clone emerged regressed to normal B-cell counts over the follow-up period. MBL was significantly more frequent in residents near a hazardous waste site than in the control populations (age-adjusted OR 6.2; 95%CI 1.1-36.2). CONCLUSION:MBL confers an elevated risk for developing a B-cell malignancy, although it occurs only in a minority of cases. PCBL is most often a transient state, but a monoclonal population can emerge and persist. Prospective studies are needed to distinguish stable from progressive forms of B-cell lymphocytosis and to clarify the etiologic role of environmental exposures. Published 2007 Wiley-Liss, Inc.
Authors: Lynn R Goldin; Mark C Lanasa; Susan L Slager; James R Cerhan; Celine M Vachon; Sara S Strom; Nicola J Camp; Logan G Spector; Jose F Leis; Vicki A Morrison; Martha Glenn; Kari G Rabe; Sara J Achenbach; Sallie D Algood; Fatima Abbasi; Laura Fontaine; Michelle Yau; Laura Z Rassenti; Neil E Kay; Timothy G Call; Curtis A Hanson; J Brice Weinberg; Gerald E Marti; Neil E Caporaso Journal: Br J Haematol Date: 2010-08-25 Impact factor: 6.998
Authors: Youn K Shim; Dannie C Middleton; Neil E Caporaso; Jane M Rachel; Ola Landgren; Fatima Abbasi; Elizabeth S Raveche; Andy C Rawstron; Alberto Orfao; Gerald E Marti; Robert F Vogt Journal: Cytometry B Clin Cytom Date: 2010 Impact factor: 3.058
Authors: Youn K Shim; Jane M Rachel; Paolo Ghia; Jeff Boren; Fatima Abbasi; Antonis Dagklis; Geri Venable; Jiyeon Kang; Heba Degheidy; Fred V Plapp; Robert F Vogt; Jay E Menitove; Gerald E Marti Journal: Blood Date: 2013-12-17 Impact factor: 22.113
Authors: Andy C Rawstron; Tait Shanafelt; Mark C Lanasa; Ola Landgren; Curtis Hanson; Alberto Orfao; Peter Hillmen; Paolo Ghia Journal: Cytometry B Clin Cytom Date: 2010 Impact factor: 3.058
Authors: Neil E Caporaso; Gerald E Marti; Ola Landgren; Elizabeth Azzato; J Brice Weinberg; Lynn Goldin; Tait Shanafelt Journal: Cytometry B Clin Cytom Date: 2010 Impact factor: 3.058
Authors: Tait D Shanafelt; Neil E Kay; Kari G Rabe; Timothy G Call; Clive S Zent; Kami Maddocks; Greg Jenkins; Diane F Jelinek; William G Morice; Justin Boysen; Susan Schwager; Deborah Bowen; Susan L Slager; Curtis A Hanson Journal: J Clin Oncol Date: 2009-07-20 Impact factor: 44.544